San Antonio Breast Cancer Symposium 2024

Dr. Nicholas Zdenkowski informs us that the authors presented their priorities in breast cancer, focusing on shared decision-making, optimizing multidisciplinary consultation, and improving data on metastatic breast cancer to better care for these patients.

Dr. Nick Zdenkowski discusses the EMBER trial on second-line ER-targeted drugs, patient-reported outcome monitoring, and the survival benefits of risk-reducing surgeries for BRCA mutant patients.

Dr. Sherene Loi discusses the development and importance of immune biomarkers in breast cancer, highlighting the TIL biomarker, the limitations of PD-L1, and the potential of new biomarkers to refine treatment algorithms and clinical trials

Dr. Nick Zdenkowski discusses the PATINA trial.

Dr. Nick Zdenkowski discusses the SUPREMO trial.

Dr. Carlos Barrios discusses the PATINA trial that was presented recently.

Dr. Nick Zdenkowski discusses the ZEST trial.

Dr. Virginia Kaklamani highlights the EMBER-3 clinical trial, which found that imlunestrant outperformed single-agent endocrine therapy in patients with ESR1 mutations and showed improvement when combined with abemaciclib, suggesting potential FDA approval.

Dr. Nick Zdenkowski discusses resistance mechanisms to CDK4/6 inhibitors.

Dr. Virginia Kaklamani discusses the PATINA trial, a phase III clinical trial.

Dr. Nick Zdenkowski discusses tumor-infiltrating lymphocytes as prognostic and predictive factors in breast cancer.